Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Harmony Gold Mining Co. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.6 (market cap $39.89B), while Harmony Gold Mining Co. trades at $15.04 (market cap $9.43B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.2× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays a 2.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HMY | |
|---|---|---|
Market Cap | $39.89B | $9.43B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $26.04 |
52-Week Low | $278.09 | $12.61 |
Enterprise Value | $38.15B | $9.77B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Harmony Gold Mining (HMY) trades at $15.11, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2024 results with $61.38B revenue and $8.59B net income, showing improved margins. Recent earnings have been mixed, beating in Q2 2025 but missing in Q4 2025. A dividend of $0.31 is scheduled for May 2026. Analyst consensus is predominantly Hold (70%), with 10% Buy and 20% Sell ratings.
HMY presents a valuation opportunity with a low P/E of 9.67 and EV/EBITDA of 5.06, supported by robust profitability metrics like 20.06% net margin and 32.32% ROE. However, risks include gold price sensitivity to Fed rate hikes, operational execution in transitioning to gold-copper hybrid model, and bearish technical trends. The stock's outlook balances fundamental strength against macroeconomic and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
